$414.24 Million in Sales Expected for Bruker Corporation (BRKR) This Quarter

Brokerages expect Bruker Corporation (NASDAQ:BRKR) to post $414.24 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Bruker Corporation’s earnings, with the highest sales estimate coming in at $420.50 million and the lowest estimate coming in at $402.00 million. Bruker Corporation posted sales of $393.90 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.2%. The company is scheduled to announce its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Bruker Corporation will report full year sales of $414.24 million for the current financial year, with estimates ranging from $1.68 billion to $1.77 billion. For the next financial year, analysts expect that the business will report sales of $1.76 billion per share, with estimates ranging from $1.70 billion to $1.80 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Bruker Corporation.

Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.03. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. The firm had revenue of $414.90 million for the quarter, compared to the consensus estimate of $384.75 million. During the same period last year, the firm earned $0.20 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis.

BRKR has been the topic of a number of recent analyst reports. BidaskClub upgraded shares of Bruker Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Wells Fargo & Co cut shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Zacks Investment Research upgraded shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Thursday, July 6th. Barclays PLC restated an “equal weight” rating and set a $30.00 price objective (up from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Finally, Cowen and Company restated a “hold” rating and set a $29.00 price objective on shares of Bruker Corporation in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. Bruker Corporation presently has a consensus rating of “Hold” and a consensus target price of $27.00.

In other Bruker Corporation news, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Frank H. Laukien purchased 2,335 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the transaction, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. 35.20% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Bruker Corporation by 2.9% in the first quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock worth $229,391,000 after acquiring an additional 277,111 shares in the last quarter. FMR LLC raised its position in Bruker Corporation by 26.4% in the first quarter. FMR LLC now owns 7,146,000 shares of the medical research company’s stock worth $166,716,000 after acquiring an additional 1,491,140 shares in the last quarter. BlackRock Inc. raised its position in Bruker Corporation by 3.0% in the second quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock worth $136,918,000 after acquiring an additional 139,792 shares in the last quarter. Boston Partners raised its position in Bruker Corporation by 3.6% in the second quarter. Boston Partners now owns 2,773,019 shares of the medical research company’s stock worth $79,973,000 after acquiring an additional 96,791 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in Bruker Corporation by 6.8% in the second quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock worth $55,667,000 after acquiring an additional 123,322 shares in the last quarter. Hedge funds and other institutional investors own 65.42% of the company’s stock.

Bruker Corporation (NASDAQ:BRKR) traded down 0.20% during trading on Thursday, hitting $29.36. 359,011 shares of the stock were exchanged. Bruker Corporation has a 12 month low of $19.59 and a 12 month high of $30.23. The stock’s 50 day moving average price is $28.57 and its 200 day moving average price is $26.57. The stock has a market cap of $4.66 billion, a P/E ratio of 29.27 and a beta of 1.10.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 22nd. Shareholders of record on Tuesday, September 5th were given a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.54%. The ex-dividend date of this dividend was Thursday, August 31st. Bruker Corporation’s dividend payout ratio (DPR) is presently 16.00%.

TRADEMARK VIOLATION NOTICE: “$414.24 Million in Sales Expected for Bruker Corporation (BRKR) This Quarter” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://transcriptdaily.com/2017/09/24/414-24-million-in-sales-expected-for-bruker-corporation-brkr-this-quarter.html.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Get a free copy of the Zacks research report on Bruker Corporation (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply